GlaxoSmithKline Pharmaceuticals (GSK) recently cut a deal with the Brazilian government, which allows it to supply a 10-valent vaccine against childhood pneumonia and other life-threatening infections for a decade at a fixed price in a reflection of the growing importance of vaccines and emerging markets to Big Pharma.